Financials data is unavailable for this security.
View more
Year on year Haleon PLC had relatively flat revenues (11.30bn to 11.23bn), though the company grew net income 37.46% from 1.05bn to 1.44bn. A reduction in the cost of goods sold as a percentage of sales from 38.40% to 36.49% was a component in the net income growth despite flat revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -- |
| Operating margin | -- |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in GBPView more
In 2024, Haleon PLC increased its cash reserves by 122.03%, or 1.21bn. The company earned 2.30bn from its operations for a Cash Flow Margin of 20.48%. In addition the company generated 528.00m cash from investing, though they paid out 1.54bn more in financing than they received.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.77 |
|---|---|
| Tangible book value per share | -1.05 |
More ▼
Balance sheet in GBPView more
| Current ratio | 0.8699 |
|---|---|
| Quick ratio | 0.6327 |
| Total debt/total equity | 0.5319 |
|---|---|
| Total debt/total capital | 0.3464 |
More ▼
Growth rates in GBP
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 10.00% and 38.78%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
| EPS growth(5 years) | 17.25 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -- |
